Rosuvastatin 20

ApprovedSmall molecule

YYonsei University

Rosuvastatin 20 is one of 87 small molecule programs targeting Cardiovascular Disease. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Cardiovascular DiseaseActive, not recruiting

Left Ventricular Diastolic DysfunctionActive, not recruiting

Vascular DiseaseActive, not recruiting

Cardiovascular DiseasePreclinical

Active, not recruiting

Left Ventricular Diastolic DysfunctionApproved

Active, not recruiting

Vascular DiseasePreclinical

Active, not recruiting

Competition

Competitive Landscape

274 competitors in Cardiovascular Disease

#DrugCompanyPhaseTrials

Kerendia

Bayer

Phase 3

1 2

Actos

Takeda

Phase 3

1 3

Jardiance

Boehringer Ingelheim

Phase 3

2 4

Zocor

OOrganon and Co

Phase 3

2 5

Livalo

MMedicure

Phase 3

1 6

Xarelto

WWim Janssens

Phase 3

1 7

Rosuvastatin 20

YYonsei University

Approved

1 8

Repatha

Amgen

Preclinical

5 9

Mounjaro

Eli Lilly

Preclinical

1 10

Praluent

Regeneron

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 2Recruiting

Function

NCT07460960

Q2 2029

N/ARecruiting

Vascular Disease

NCT06231966

Clinical

Trials by Indication[1]

Cardiovascular Disease1 trial

RAndomized Comparison of Efficacy and Safety of Lipid-lowerING With Statin Monotherapy Versus Statin/Ezetimibe Combination for High-risk Cardiovascular Diseases (RACING Trial)

Unknown status·YYonsei University·N/A·NCT03044665·3,780 enrolled

Vascular Disease1 trial

Randomized Comparison of Efficacy and Safety of High-intensity Rosuvastatin/Ezetimibe Combination Versus Treat-to-target Rosuvastatin Monotherapy for Patients With Peripheral Artery or Polyvascular Disease (CARE-PVD Trial)

Recruiting·YYonsei University·N/A·NCT06231966·2,462 enrolled

Left ventricular diastolic dysfunction1 trial

Compare the Efficacy and Safety of Rosuvastatin/Ezetimibe Combination Therapy Versus Rosuvastatin Monotherapy in Korean Patients With Left Ventricular Diastolic Dysfunction and Hyperlipidemia

Unknown status·YYonsei University·Phase 4·NCT04433533·200 enrolled

Function1 trial

TRIal of STatin Therapy Effect on Androgen Status and Erectile functioN in Men

Recruiting·LLomonosov Moscow State University Medical Research and Educational Center·Phase 2·NCT07460960·150 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Rosuvastatin 20. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Rosuvastatin 20 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Rosuvastatin 20. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Yonsei University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: YYonsei University

Rosuvastatin 20

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q2 2029

Trials by Indication[1]

Cardiovascular Disease1 trial

Vascular Disease1 trial

Left ventricular diastolic dysfunction1 trial

Function1 trial

References

Drug Info

Quick Facts

Related News